Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-guided prophylactic factor dosing in hemophilia
NL-OMON27791Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of Factor VIII and coagulation factor ix in hemophilia A and hemophilia B (HB) (4 arms), sponsored by Erasmus MC. Primary endpoint: Observed versus predicted factor trough and peak levels. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
Factor VIIIcoagulation factor ix
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON27791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27791.